Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is

Aryl optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halogen, C_{1-6}alkylCO-, $-(CH_2)_mOH$, -CN, R^7R^8N-;

Aryl fused to a C_{4-7}cycloalkyl ring;

Aryl fused to a heterocyclyl ring;

Heteroaryl wherein the heteroaryl is optionally substituted by one or more substituents selected from: C_{1-6}alkyl, N-oxide, C_{1-6}alkoxy; or

Heterocyclyl.

R^2 is hydrogen or C_{1-6}alkyl;

Express Mail Label No.
EV 332064819 US

R^3 is

Hydrogen;

C_{1-6}alkyl optionally substituted by one or more substituents selected from: heterocyclyl (itself optionally substituted by C_{1-6}alkyl), $R^9R^{10}NCO$-, $R^{11}CONR^{12}$-, C_{1-6}alkylSO_2NR^{13}-, C_{1-6}alkoxy, $R^{14}R^{15}N$-;

C_{3-7}cycloalkyl;

Aryl or aryl(C_{1-6}alkyl) wherein the aryl is optionally substituted by one or more substituents selected from: C_{1-6}alkyl, C_{1-6}alkoxy, halogen, $R^{16}R^{17}NCO$-;

Aryl fused to C_{4-7}cycloalkyl, wherein the cycloalkyl is optionally substituted by =O;

Heteroaryl or heteroaryl(C_{1-6}alkyl), wherein the heteroaryl is optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy, halogen; or

Heterocyclyl optionally substituted by one or more C_{1-6}alkyl, C_{1-6}alkylCO-, C_{1-6}alkylSO_2-, $R^{18}R^{19}NCO$-, C_{1-6}alkoxyCO-;

R^4 is hydrogen or C_{1-6}alkyl;

R^3 and R^4 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which is optionally substituted by one or more substituents selected from C_{1-6}alkyl (optionally substituted by one or more OH or C_{1-6}alkoxy groups), C_{1-6}alkoxy, C_{1-6}alkoxyCO-, C_{3-7}cycloalkyl (optionally substituted by OH), C_{1-6}alkylCO-, C_{1-6}alkylSO_2-, OH, -$(CH_2)_mNR^{20}R^{21}$, -$(CH_2)_mCONR^{22}R^{23}$, -$(CH_2)_mNR^{24}COR^{25}$, C_{1-6}alkoxyC_{1-4}alkyl, arylCO- heteroaryl, heteroarylC_{1-4}alkyl, heteroarylCO.

m is 0-6

R^5 is hydrogen or C_{1-6}alkyl;

R^6 is hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, fluorine, chlorine, or bromine;

R^{7-25} all independently represent hydrogen, or C_{1-6} alkyl;

R^{14} and R^{15} together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R^{16} and R^{17} together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R^{18} and R^{19} together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R^{20} and R^{21} together with the nitrogen atom to which they are attached may form a heterocyclyl ring; and

R^{22} and R^{23} together with the nitrogen atom to which they are attached may form a heterocyclyl ring.

2. (Currently Amended) A compound according to claim 1 wherein R^1 is selected from

aryl optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{1-6}alkoxy-, halogen, -CN;

aryl fused to a heterocyclyl ring; and

heteroaryl optionally substituted by one or more substituents selected from: C_{1-6}alkyl.

3. (Currently Amended) A compound according to claim 1 ~~or 2~~ wherein R^2 is hydrogen.

4. (Currently Amended) A compound according to ~~any of~~ claims 1 ~~to 3~~ wherein R^3 is selected from

C_{1-6}alkyl optionally substituted by one or more substituents selected from heterocyclyl, C_{1-6}alkoxy;

C_{3-7}cycloalkyl; and

Heterocyclyl.

5. (Currently Amended) A compound according to ~~any of~~ claims 1 ~~to 4~~ wherein R^4 is hydrogen or C_{1-6}alkyl.

6. (Currently Amended) A compound according to ~~any of~~ claims 1 ~~to 3~~ wherein R^3 and R^4 together with the nitrogen atom to which they are attached ~~may~~ form a heterocyclyl ring, optionally substituted by one or more substituents selected from C_{1-6}alkyl (optionally substituted by one or more C_{1-6}alkoxy groups), C_{1-6}alkylCO, C_{1-6}alkylSO_2; $-(CH_2)_mCONR^{22}R^{23}$, $-(CH_2)_mNR^{20}R^{21}$, heteroaryl.

7. (Currently Amended) A compound according to ~~any of~~ claims 1 ~~to 6~~ wherein R^5 is hydrogen.

8. (Currently Amended) A compound according to ~~any of~~ claims 1 ~~to 7~~ wherein R^6 is hydrogen or C_{1-6}alkyl.

9. (Currently Amended) A compound according to claim 1 wherein

R^1 is selected from

phenyl optionally substituted by one or more substituents selected from methyl, methoxy, fluoro, chloro, cyano;
dihydrobenzofuranyl; and
indazolyl or benzimidazolyl optionally substituted by methyl;

R^2 is hydrogen;

R^3 is selected from
C_{1-3}alkyl optionally substituted by one C_{1-2}alkoxy group or a 5 to 7 membered saturated ring containing one or two heteratoms selected from nitrogen or oxygen;
C_{3-5}cycloalkyl; and
5 to 7 membered saturated ring containing one heteroatom which is oxygen;

R^4 is hydrogen or C_{1-6}alkyl;

R^5 is hydrogen;

R^6 is hydrogen or C_{1-6}alkyl.

10. (Currently Amended) A compound according to claim 1 wherein

R^1 is selected from

phenyl optionally substituted by one or more substituents selected from methyl, methoxy, fluoro, chloro, cyano;
dihydrobenzofuranyl; and
indazolyl or benzimidazolyl optionally substituted by methyl;

R^2 is hydrogen;

R^3 and R^4 together with the nitrogen atom to which they are attached may form a 5 or 6 membered heterocyclyl ring, optionally substituted by one or more substituents selected from C_{1-3}alkyl (optionally substituted by one or more C_{1-}

$_2$alkoxy groups), C_{1-3}alkylCO, C_{1-3}alkylSO$_2$; -CON(CH$_3$)$_2$, -N(CH$_3$)$_2$, pyrazinyl, pyridinyl;

R^5 is hydrogen; and

R^6 is hydrogen or C_{1-6}alkyl.

11. (Previously Presented) A compound of formula (I) selected from the group consisting of

6-[(dimethylamino)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide;

6-[(4-acetyl-1-piperazinyl)sulfonyl]-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide;

4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-{[4-(methylsulfonyl)-1-piperazinyl]sulfonyl}-3-quinolinecarboxamide;

6-[(4-acetyl-1-piperazinyl)sulfonyl]-4-(2,3-dihydro-1-benzofuran-4-ylamino)-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[4-(methylsulfonyl)-1-piperazinyl]sulfonyl}-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-[(dimethylamino)sulfonyl]-3-quinolinecarboxamide;

6-({4-[(dimethylamino)carbonyl]-1-piperazinyl}sulfonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[4-(2-pyrazinyl)-1-piperazinyl]sulfonyl}-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-({4-[(dimethylamino)carbonyl]-1-piperazinyl}sulfonyl)-3-quinolinecarboxamide;

4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-[(tetrahydro-2*H*-pyran-4-ylamino)sulfonyl]-3-quinolinecarboxamide;

4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide

4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
8-methyl-4-[(3-methylphenyl)amino]-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
4-[(3-fluorophenyl)amino]-8-methyl-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
4-[(3-cyanophenyl)amino]-8-methyl-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[4-(dimethylamino)-1-piperidinyl]sulfonyl}-3-quinolinecarboxamide
4-[(3-chlorophenyl)amino]-8-methyl-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(4-morpholinylsulfonyl)-3-quinolinecarboxamide
6-[(4-acetyl-1-piperazinyl)sulfonyl]-8-methyl-4-[(3-methylphenyl)amino]-3-quinolinecarboxamide
6-[(4-acetyl-1-piperazinyl)sulfonyl]-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide
6-[(4-acetyl-1-piperazinyl)sulfonyl]-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide

and pharmaceutically acceptable salts thereof.

12. (Currently Amended) A process for the preparation of a compound of formula (I) and pharmaceutically acceptable salts thereof as defined in ~~any of~~ claim~~s~~ 1 ~~to 11~~ which comprises:

(A) reacting a compound of formula (II);



(II)

wherein R^3, R^4, R^5 and R^6 are as defined above, and X represents a halogen atom, with an amine of formula R^1R^2NH, wherein R^1 and R^2 are as defined above; or

(B) interconversion of a compound of formula (I) into another compound of formula (I); or

(C) deprotecting a protected derivative of a compound of formula (I).

13.-14. (Canceled).

15. (Currently Amended) A method of treating an inflammatory and/or allergic disease in a mammal in need thereof, which comprises administering to the mammal a therapeutically effective amount of a compound of formula (I) according to ~~any of~~ claim~~s~~ 1 ~~to 11~~, or a pharmaceutically acceptable salt thereof.

16. (Currently Amended) A pharmaceutical composition which comprises a compound according to ~~any of~~ claim~~s~~ 1 ~~to 11~~, or a pharmaceutically acceptable salt thereof ~~optionally~~ with a pharmaceutically acceptable carrier or excipient.

17. (Previously Presented) A pharmaceutical composition according to claim 16 which is suitable for inhaled administration.

18. (Previously Presented) A pharmaceutical composition according to claim 16 which is suitable for oral administration.

19. (Previously Presented) A pharmaceutical composition according to claim 16 which is suitable for topical administration.

20. (New) A method of inhibiting PDE4, comprising the administration of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

Express Mail Label No.
EV 332064819 US